Aurobindo Pharma (India)

[ 177 Lu]Lu‐PSMA‐617 Plus Short‐Course Priming With Enzalutamide in Metastatic Castration‐Resistant Prostate Cancer: A Single‐Arm Phase 2 Trial (Lu‐PRIME)

ABSTRACT Background [ 177 Lu]Lu‐PSMA‐617 has been an approved treatment modality for metastatic castration‐resistant prostate cancer (mCRPC). Recent studies have shown PSMA upregulation following enzalutamide, which may enhance the outcomes with [ 177 Lu]Lu‐PSMA‐617. This study a...